Neurocrine Biosciences | Capitale Sociale E Riserve



Equity Capital And Reserves Cambiamento Data
AbbVie USD 3.32B 2.71B 2024-12
Acadia Pharmaceuticals USD 765.24M 32.44M 2025-03
Agios Pharmaceuticals USD 1.47B 74.43M 2025-03
ALKERMES USD 1.51B 46.61M 2025-03
Alnylam Pharmaceuticals USD 115.43M 48.35M 2025-03
Amgen USD 6.21B 330M 2025-03
Biogen USD 16.98B 262.7M 2025-03
BioMarin Pharmaceutical USD 5.79B 135.47M 2025-03
Cytokinetics USD -266413000 131.04M 2025-03
Dynavax Technologies USD 530.94M 65.86M 2025-03
Exelixis USD 2.13B 113.18M 2025-04
Gilead Sciences USD 19.33B 856M 2024-12
Halozyme Therapeutics USD 482.27M 118.45M 2025-03
Incyte USD 3.67B 219.94M 2025-03
Ionis Pharmaceuticals USD 475.73M 112.62M 2025-03
Neurocrine Biosciences USD 2.59B 129.2M 2024-12
Pfizer USD 90.34B 2.14B 2025-03
Prothena USD 486.93M 47.44M 2024-12
Regeneron Pharmaceuticals USD 29.39B 34M 2025-03
Repligen USD 1.99B 12.76M 2025-03
Sarepta Therapeutics USD 1.14B 385.02M 2025-03
Teva Pharmaceutical Industries USD 6.26B 542M 2025-03
Ultragenyx Pharmaceutical USD 144.25M 111.05M 2025-03
Vertex Pharmaceuticals USD 16.41B 778.7M 2024-12



Neurocrine Biosciences Capitale Sociale E Riserve - Valori correnti, dati storici, previsioni, statistiche, grafici e calendario economico - May 2025.